THE TEAM BEHIND MOLOGIC
Mologic started out in 2003 with just 12 employees and we’ve now grown to a team of over 60. We take pride in the fact that our people are at the top of their game, whatever their specialism. They’re hand-picked from leading universities, research institutions and companies as well as from diverse backgrounds, skill sets and personalities.
Together, the Mologic team can offer the full spectrum of scientific, manufacturing, product development and marketing skills required to create the research and products you need. We nurture our people’s individuality, flexibility and ability to think outside the box, encouraging innovative thinking and brave decision-making. Every member of our team is part of our success story, and has an impact on the work we do.
A US national who came to the UK in 2008, Chris has 25 years’ success in bringing new medical products from concept to market adoption in VC and Fortune 500 companies, raising over $50M funding from investors. Previously CEO of GlySure, Chris is currently chairman of Elasmogen, and non-executive director for MediSieve, Causeway Therapeutics, Deltex Medical, and Health Enterprise East.
Mark has over 20 years’ experience in R&D, sales, marketing and management of life science and diagnostic companies. With experience gained in both large-cap and start-up companies, covering everything from benchwork to sales and technical support, Mark co-founded Mologic Ltd in 2003.
Paul has worked in immunology for 45 years and has founded or co-founded eight bioscience businesses since 2002, with Mologic being the most prominent. As Mologic’s chief scientific officer, Paul leads the Centre for Advanced Rapid Diagnostics (CARD), funded by the Bill & Melinda Gates Foundation. Until 2002 he was as a senior scientist at Unilever Research, leading applied immunology, and is one of the inventors of the lateral flow immunoassay.
A fellow of the ACCA (Association of Chartered Certified Accountants), Dan qualified in 2010 and worked for a leading firm of chartered accountants before moving into industry. Following a senior accountant role at Lockheed Martin UK, he joined Mologic in 2012 as chief accountant, becoming chief financial officer in 2015.
Before joining Mologic, where he oversees our clinical and global health activities, Joe was a program officer at the Bill & Melinda Gates Foundation, where he advanced its bilateral partnerships with EU donors, including the manufacturing capacity of yellow fever vaccine and infectious disease surveillance and control at the Institut Pasteur in Dakar. Previously he was a Frank Knox Fellow in public health and infectious disease epidemiology at Harvard University, focusing on the impact of global policy on vaccines, drugs, and access to health technologies.
Tim is a Chartered Biologist and a Fellow of the Royal Society of Biology and has over 19 years of experience leading the design and development diagnostic devices on multiple immunoassay platform technologies. Tim has made significant leadership and scientific contributions at AgPlus Diagnostics, Novartis, Vivacta, Oxonica and Oxford Immunotec where he was one of the original scientists responsible for the company’s first product T-SPOT-TB™.
